Allos third one fourth net reduction decreases to $11.2 million Allos Therapeutics, Inc. today reported economic results for the 90 days ended September 30, 2011 tadacip .2 million in the third quarter of 2011, in comparison to $8.2 million for the same period in 2010 2010. As of 30 September, 2011, the business had no debt and $100.4 million in total cash, cash equivalents and investments. ‘We believe our achievement of significant year-over-year revenue development reflects increased disease-state recognition and brand awareness of FOLOTYN for individuals with relapsed or refractory peripheral T-cell lymphoma, for whom there remains an unmet need,’ commented Paul L. Berns, president and chief executive officer of Allos Therapeutics.
Is usually trending towards delivering top quality and more cost effective care, and Apixio’s alternative when combined with Sunrise from Allscripts might help healthcare businesses achieve these goals.’.. Allscripts approves Apixio Community Search product Apixio Inc., the leading provider of clinical integration and medically intelligent search solutions for private health data, announced that it is Community Search product has been tested and approved by Allscripts and is now featured in the Allscripts Program Store and Exchange on the business’s ClientConnect website. Apixio is normally on the market for users of Sunrise Clinical Manager 5.5.S. Can be trending towards delivering higher quality and more cost effective care, and Apixio’s remedy when coupled with Sunrise from Allscripts might help healthcare institutions obtain these goals.